PHARMACOGENETICS – THE FUTURE OF THE DRUG THERAPY by Slobodan Jankovic & Natasa Djordjevic
www.medfak.ni.ac.yu/amm 
 
56
Review article 
 
 
 
 
 
 
 
 
PHARMACOGENETICS – THE FUTURE OF THE DRUG THERAPY 
 
 
Natasa Djordjevic and Slobodan Jankovic 
 
 
Individual variation in response to drugs is an important clinical problem, which 
ranges from failure to respond to a drug to adverse drug reactions. Medical therapy still 
aims at the broadest patient population that might possibly benefit from it, relying on 
statistical analysis of this population's response for predicting therapeutic outcome. Yet, 
certain percentage of patients will obtain no benefit from a given drug, or will experience 
toxicity. Pharmacogenetics, which deals with the genetic basis underlying variable drug 
response, offers the potential of individualizing drug therapy, and through optimizing 
efficacy and minimizing toxicity it increases the possibility for a wide range of diseases 
to be cured and controlled. Acta Medica Medianae 2007;46(2):56-60. 
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The definition 
 
Individual variation in response to drugs is 
an important clinical problem, which ranges from 
failure to respond to a drug to adverse drug 
reactions and drug-drug interactions when seve-
ral drugs are taken concomitantly (1). Many non-
genetic factors (including age, organ function and 
nature of the disease) influence the effects of 
medications, but it is estimated that genetics can 
account for 20 to 95% of variability in drug 
disposition and effects (2). The genetic consti-
tution of an individual, as extremely relevant 
factor for both efficacy and safety of a given drug 
regimen (3), makes the central topic of pharma-
cogenetics, as a special scientific discipline arised 
from the confluence of genetics, biochemistry, 
and pharmacology (4).  
Pharmacogenetics has been defined as the 
science of pharmacological response and its 
modification by hereditary influence; the subjects 
of interest relate both to efficacy (therapeutic 
effectiveness) and toxicity (production of side 
effects or unwanted effects) (5). Dealing with the 
genetic basis which underlies variable drug 
response in individual patients, it develops an 
individualized approach to the therapy, where opti-
mally effective drugs are matched to a patient's 
unique genetic profile (4). Pharmacogenetics pro-
vides insight into the molecular level of drug 
function and, as a consequence, offers the po-
tential of individualized drug therapy (6). Thus it 
can help in optimizing drug efficacy and mini-
mizing adverse drug reactions (7). 
The terms ″pharmacogenomics″ and ″phar-
macogenetics″ can be considered to be almost 
synonymous (8), but pharmacogenomics can 
best be defined as the application of whole-
genome technologies for the prediction of the 
sensitivity or resistance of an individual’s disease 
to a single drug or group of drugs (9). 
 
Historical perspective 
 
It is now well-known that all humans are 
remarkably similar, in fact 99.9% identical, at the 
level of their deoxyribonucleic acid sequence 
(10). The field of genetics thus has evolved to 
include the study of inter-individual genomic 
variation, focusing on the 0.1% of our genome 
that makes each individual genetically unique 
(11). In 1902, British physician and pioneer in 
medical genetics, Sir Archibald Garrod, studying 
alcaptonuria in humans, published a paper about 
″inborn errors of metabolism″ (12). Pharma-
cogenetics as a science was born in the 1950s 
when it was reported that several therapeutic 
accidents could be hereditary (13), meaning that 
they can be induced by genetic variations of 
enzyme activity. The concept of pharmacogenetics 
originated from the clinical observation of 
patients with very high or very low plasma or 
urinary drug concentrations, which indicated 
exceptional phenotypes (14), and one of the first Acta Medica Medianae 2007,Vol.46                                                                  Pharmacogenetics – the future of the drug therapy 
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described was haemolysis after antimalarial the-
rapy occurring in persons who expressed defi-
ciency in glucose-6-phosphate-dehydrogenase 
(15). Those discoveries marked the beginning of 
a pharmacogenetics as a new clinical discipline, 
which now has applications in many fields, 
including drug development and therapeutic 
dosing guidance (16).  
Over the last 50 years, a number of events 
led the research toward the identification of 
differences in drug response of individual patients 
(6): in 1957 genetic traits and enzyme defici-
encies were described as causes for idiosyncratic 
drug reactions, in 1959 Friedrich Vogel coined the 
term ″pharmacogenetic″, defining it as ″clinically 
important hereditary variations″, in 1962 first 
book about pharmacogenetics was published by 
Werner Kalow, in 1977 the polymorphic hydro-
xylation of debrisoquine in men was described 
and in 1988 common genetic defect in the 
CYP2D6 gene in humans deficient in debrisoquine 
metabolism was characterized. In 2003, 50 years 
after the famous publication on DNA structure by 
James Watson and Francis Crick (17), ″The 
Human Genome Project″ was completed, which 
provided the new opportunities in using genetic 
information for individualizing drug therapy (18).  
 
Pharmacogenetics polymorphism  
 
The term pharmacogenetic polymorphism 
defines a monogenetic trait, caused by the 
presence of more than one allele at the same 
locus and more than one phenotype in the same 
population in regard to drug interaction with the 
organism, with the frequency of the rarest allele 
of more than 1% (19).  DNA sequence variations 
may occur as insertions or deletions of nucle-
otides, differences in the copy number of 
repeated sequences or SNPs - Single Nucleotid 
Polymorphisms (20, 21). If the mutations occur 
in proteins that are drug targets or drug-
metabolizing enzymes, or in proteins that are 
involved in drug transport mechanisms, they can 
affect drug efficacy and safety (15). 
Genetic polymorphism in drug metabolism, 
according to their ability to perform a certain 
drug biotransformation reaction, defines three 
distinct populations: poor metabolizers (PM), 
extensive metabolizers (EM) and ultrarapid 
metabolizers (UM). The PM phenotype is mono-
genically inherited as an autosomal recessive 
trait and it is due to complete absence or marked 
decrease in the amount and/or activity of the 
enzyme. The poor metabolizers are unable to 
metabolize drug to the full extent, so the clinical 
consequences of the PM phenotype are the side 
effects and toxicity after administration of an 
active drug; if the metabolite has the therapeutic 
effect, a therapeutic failure may be expected 
after giving the prodrug (22). On the other hand, 
the UM phenotype is due to the presence of 
duplicated genes resulting in expression of 
increased amount of enzyme. The clinical 
consequence of the UM phenotype is the inability 
to reach therapeutic plasma-concentrations after 
administration of an active drug in a usual dose, 
which results in a therapeutic failure; admini-
stration of a prodrug may cause toxicity (23). The 
EM phenotype is the most common and it 
represents the norm for standard dosing practi-ces 
in drug administration. Their metabolizing capacity 
depends on whether they are homozigous or 
heterozigous for the active form of the gene 
producing the drug metabolizing enzyme (24).  
 
Clinical applications 
 
Understanding of the genetic variations and 
their influence on individual response to drug 
therapy increases the possibility for a wide range 
of diseases to be cured and controlled. Many 
different drugs can illustrate the clinical impor-
tance of pharmacogenetics. 
There was significant advance in treating 
elevated blood pressure over the last decades, 
yet hypertension continues to be a major public 
health problem (25). Despite the great number of 
antihypertensive drugs that are available, in 
between half and two-thirds of treated hyper-
tensive patients blood pressure control stays 
suboptimal, while adverse effects represent 
approximately 80% of the causes for the 
discontinuity of the antihypertensive therapy 
(26,27). One of the drugs frequently used for 
lowering blood pressure in patients with 
hypertension is metoprolol. It is a β1-blocking 
drug extensively metabolized in the liver, mostly 
under control of polymorphic drug-metabolizing 
enzyme cytochrome P450 2D6 (CYP2D6), a 
major determinant of interindividual differences 
in  metoprolol plasma clearance (28, 29). It has 
been found that poor metabolizers (PM) exhibit 
3- to 10-fold higher plasma concentrations after 
administration of metoprolol than extensive 
metabolizers (EM), while ultrarapid metabolizers 
(UM) achieve metoprolol concentrations that are 
half those observed in EMs (30), which shows a 
strong gene-concentration relationship (29). In 
terms of a gene-effect relationship, metoprolol 
has been reported to produce a more intense and 
prolonged β-blockade in PM than in EM subjects 
(31). Therefore, while PMs would require only 
once-daily treatment with metoprolol 100 mg for 
effective blood pressure control, EMs would 
usually require twice-daily treatment with 
metoprolol 100 mg (32). Furthermore, since the 
mRNA for CYPD6 has been found to be 
predominantly expressed in the right ventricle 
(33), the genetic polymorphism of CYP2D6 can 
be considered as an important risk factor in 
treating cardiovascular patients with metoprolol 
and the genotyping should be used to estimate at 
least the initial dose required (34). 
The treatment of epilepsy offers another 
opportunity for the application of pharmacoge-
netics into clinical practice, because of the wide 
variety of individual responses to antiepileptic 
drugs that leads to adverse drug reaction (35) or 
inadequate seizure control (36) in half of the 
patients currently treated with antiepileptics (37, 
38). One of the important and effective antie-
pileptic drugs is phenytoin, widely prescribed 
throughout the world, but narrow therapeutic Pharmacogenetics – the future of the drug therapy                      Natasa Djordjevic et al. 
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index of the drug makes it difficult, time con-
suming and expensive for finding out the correct 
dose (39, 40). Phenytoin is almost completely 
metabolized in the liver, and many studies clearly 
indicate that the main enzyme involved in 
phenytoin clearance is CYP2C9, which is 
responsible for up to 90% of drug inactivation 
(40-42). Yet, the evidence about contribution of 
CYP2C19, which increases with increase in 
phenytoin concentrations, suggest that CYP2C19 
might be important when CYP2C9 is saturated 
(42). The activity of CYP2C9 varies up to 10-fold 
in vivo, with one in every 500 individuals exhibits 
deficient activity of this enzyme (43), while 
several genetic variants of CYP2C19 that have 
been reported cause the poor metabolizer 
phenotype in approximately 10% of Caucasians 
(44). Several studies of phenytoin have shown 
that variations in the genes CYP2C9 and CYP2C19 
correlate with the maximum dose of drug needed 
by patients to control their seizures: patients who 
were poor metabolisers for these genes needed 
up to 75% lower dose of phenytoin than the 
extensive metabolisers to achieve the therapeutic 
concentrations of the drug in serum (45-47). 
Because of  the narrow therapeutic index of 
phenytoin, minimum toxic serum concentration 
can be easily exceeded even with the moderate 
doses that are given during induction of therapy; 
thus it becomes clear that genotyping for CYP2C9 
and CYP2C19 allelic variants could, together with 
serum drug concentration monitoring, facilitate 
and accelerate a proper phenytoin induction and 
decrease the risk of intoxications, contributing to 
the individualization and optimalization of the 
therapy (46). 
It is estimated that 15% of the population 
will develop depression during their lifetime, and 
that the prevalence is 5% (48). Depression is a 
severe disorder that needs to be treated, yet 
about 30–50% of patients will not respond 
sufficiently to the therapy, regardless of the 
initial choice of standard psychiatric medication 
(49,50). In the disposition of tricyclic antidepre-
ssant nortriptyline, widely used in the treatment 
of patients with depression, noticeable inter-
individual variability has been well- documented 
(51). Plasma concentrations of this drug, with 
metabolism up to 80% mediated by the highly 
polymorphic enzyme CYP2D6 (29), have been 
shown to vary in relation to CYP2D6 genotype 
(51), and many studies supported the existence 
of a concentration-effect relationship for the 
antidepressant action (52). There are several 
case reports documenting toxicity due to ele-
vated nortriptyline concentrations in PMs lacking 
CYP2D6 activity, but also treatment failures in 
UMs with multiduplicated functional gene (48): 
individual response thus can vary remarkably, 
ranging between experiencing adverse effects 
early in the course of therapy (53) and not being 
able to reach therapeutic plasma concentrations 
even with doses of drug much higher than usual 
(54). Although only 20% of ultrarapid 
metabolizers can be predicted from the results of 
genotyping, testing for a limited set of CYP2D6 
alleles may distinguish with almost 100% accu-
racy the vast majority of Caucasian individuals 
lacking CYP2D6 activity (53), therefore prior 
knowledge of the CYP2D6 genotype have poten-
tial to improve the choice of initial dosage of 
nortriptyline to the individual patient (51).  
Interindividual variability in response to 
drug therapy is the rule, not the exception, for 
almost all medications (55). Having that in mind, 
the need for translation of pharmacogenetics 
from laboratories to the bedside can be easily 
understood.  
 
The goals 
 
Medicine of the third millennium still tar-
gets therapy to the broadest patient population 
that might possibly benefit from it, and it relies 
on statistical analysis of this population's 
response for predicting therapeutic outcome in 
individual patients. However, any given drug can 
be therapeutic in some individuals but ineffective 
in others, and some individuals can experience 
adverse drug effects while others can be 
unaffected. Recognition of those inter-individual 
differences in drug response is an essential step 
towards optimizing therapy (4).  
Currently there are two main treatment 
approaches in the pharmacological management 
of disease: trial and error approach and per 
protocol approach. The first is employed for drug 
treatment of diseases such as hypertension, 
diabetes and depression, where several drugs are 
considered as a reasonable first line therapy: trial 
and error approach means finding the drug(s) 
that is most effective in a given patient, and can 
often take months to accomplish. When the 
treatment for a given disease is essentially the 
same for everyone with that diagnosis, e.g. most 
cancers, heart failure and myocardial infarction, 
per protocol approach is mainly used. Whatever 
the approach is, a certain percentage of patients 
will obtain no benefit from a given drug, or will 
experience serious adverse effects. The clinical 
application of pharmacogenetics, thus, has two 
main goals: to predict the patients at high risk of 
toxicity (and in whom a lower dose or a different 
drug should be administered) and to indicate 
those who are most likely to obtain the desired 
therapeutic effect from the drug (56). Phar-
macogenetics is expected to improve, even to 
overturn, current approaches to drug treatment 
by reducing adverse reactions, increasing drug 
efficacy and refining prescribing practices (10). 
It is now clear that virtually every pathway 
of drug metabolism will eventually be found to 
have genetic variation. However, the overall 
pharmacologic effects of medications, influenced 
by metabolism, but by apsorption, distribution, 
excretion and the drug target itself as well, are 
usually determined by the interplay of several 
genes encoding proteins involved in both phar-
macokinetics and pharmacodynamics (15). Thus 
the field of pharmacogenetics, which began with 
a focus on drug metabolism and monogenetic 
traits, has been extended and nowadays covers Acta Medica Medianae 2007,Vol.46                                                                  Pharmacogenetics – the future of the drug therapy 
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the full spectrum of drug disposition and the role 
of multiple genes (57, 58). Today there is a syste-
matic search to identify functionally significant 
variations in DNA sequences in genes that influ-
ence the effects of various drugs (12). The poten-
tial benefits of increased understanding of pharma-
cogenetic variation are choosing the right drug 
and adjusting dosage (59). The ultimate goal for 
the future is to develop individualized effective 
and safe therapies based on a predetermined 
individual genomic profile (60). 
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FARMAKOGENETIKA – BUDUĆNOST MEDIKAMENTOZNE TERAPIJE 
 
Nataša Đorđević i Slobodan Janković 
 
Individualne varijacije u odgovoru na lekove važan su klinički problem i kreću se od 
potpunog odsustva reakcije na lek do pojave neželjenih reakcija. Medicina i dalje usme-
rava terapiju ka najširoj populaciji bolesnika koji od nje mogu imati koristi, oslanjajući se 
na statističke analize u predviđanju ishoda lečenja. Ipak, određeni broj bolesnika neće 
imati nikakve koristi od primenjene terapije ili će biti intoksicirani. Ispitujući genetsku 
osnovu koja uzrokuje individualne varijacije u odgovoru na lekove, farmakogenetika omo-
gućava individualizaciju medikamentozne terapije, te postizanjem optimalne efikasnosti i 
smanjenjem pojave neželjenih efekata lekova povećava mogućnost kontrolisanja i lečenja 
velikog broja oboljenja. Acta Medica Medianae 2007;46(2):56-60.  
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